Drug Approval | January 08, 2026
Briefs: Medicamen Biotech and Gland Pharma
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Cenexi reports an EBITDA breakeven for the quarter
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
